title: Long-term radiographic outcome of nodular bronchiectatic Mycobacterium avium complex pulmonary disease.
abstract: BACKGROUND
  Although Mycobacterium avium complex pulmonary disease (MAC-PD) is a growing health problem, little is known about long-term radiographic outcome and factors for deterioration in patients with MAC-PD.
  
  
  METHODS
  Data on patients with nodular bronchiectatic (NBE)  MAC-PD who underwent regular follow-up for >5 years were retrospectively reviewed. Changes in plain chest radiograph (CXR) and baseline characteristics were compared between the stable and deteriorated groups.
  
  
  RESULTS
  Seventy-two patients were investigated, including 30 patients who  were examined 10 years after the initial visit. One patient (1.4%) showed progressive or remarkably progressive disease on CXR at 1 year; this rate increased to 22.2% at 5 years and to 53.3% at 10 years. Body mass index (BMI) at the initial visit was lower in the deteriorated group than in  the stable group. Cavitary disease and resistance to a macrolide were seen more frequently at the initial visit in the deteriorated group than in the stable group.
  
  
  CONCLUSIONS
  NBE MAC-PD is a slowly but substantially progressive long-term infection (5-10 years). Our data suggest  that patients with lower BMI, cavitary disease and resistance to a macrolide at initial visit are more likely to progress to deteriorating disease.
authors.affiliation: Department of Respiratory Medicine, National Hospital Organisation National Toneyama Hospital, Toyonaka-shi, Osaka, Japan. kitadase@toneyama.go.jp
authors.forename: S
authors.initials: S
authors.lastname: Kitada
authors.forename: T
authors.initials: T
authors.lastname: Uenami
authors.forename: K
authors.initials: K
authors.lastname: Yoshimura
authors.forename: Y
authors.initials: Y
authors.lastname: Tateishi
authors.forename: K
authors.initials: K
authors.lastname: Miki
authors.forename: M
authors.initials: M
authors.lastname: Miki
authors.forename: H
authors.initials: H
authors.lastname: Hashimoto
authors.forename: T
authors.initials: T
authors.lastname: Fujikawa
authors.forename: M
authors.initials: M
authors.lastname: Mori
authors.forename: K
authors.initials: K
authors.lastname: Matsuura
authors.forename: M
authors.initials: M
authors.lastname: Kuroyama
authors.forename: R
authors.initials: R
authors.lastname: Maekura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015992:Body Mass Index; D001987:Bronchiectasis / Q000000981:diagnostic imaging*; D015331:Cohort Studies; D018450:Disease Progression; D024881:Drug Resistance, Bacterial; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D018942:Macrolides / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015269:Mycobacterium avium Complex / Q000187:drug effects / Q000302:isolation & purification*; D015270:Mycobacterium avium-intracellulare Infection / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000382:microbiology; D011859:Radiography; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D018942:Macrolides